关于
CVS拥有Aetna健康保险、CVS药房和Caremark药品福利管理业务。
通常是什么在影响股价
Aetna旗下Medicare业务的医疗成本趋势和药品报销政策变化,驱动着股价。
人均创收
截至2025/FY,员工人数为300,000(同比+0.0%)。人均创收为总营收除以员工人数——是粗略的生产效率指标,不是员工薪酬数字。
管理团队
David Joyner serves as Chairman and CEO of CVS Health. He leads more than 300,000 colleagues who are united around the ambition to be America's most trusted health care company - and driven to simplify health care, one person, one family and one community at a time. Under his leadership, CVS Health delivers a coordinated approach to care that is affordable and accessible. Through its connected businesses, including insurance plans, pharmacies, clinics and health services, the company serves approximately 185 million people across America. With nearly four decades of experience in health care and pharmacy benefit management, David has been a catalyst for systemic change across the industry. Before becoming Chairman and CEO, David led the company's pharmacy benefit manager, CVS Caremark. He began his career at Aetna as an employee benefit representative. David holds a bachelor's degree in finance from The Rawls College of Business at Texas Tech University, where he currently sits on the advisory council.
Prem S. Shah, Executive Vice President and Group President of CVS Health Corporation since November 2024; Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation from November 2021 through November 2024 and President or Co-President of Retail from January 2022 through November 2024; Executive Vice President, Specialty and Product Innovation, CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.
Mr. Mahoney has been the President of Boston Scientific Corporation (Boston Scientific), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc. Other Public Board: Boston Scientific Corporation. Education: B.B.A., University of Iowa; M.B.A., Wake Forest University.
Mr. Aguirre is the former Chairman, President and Chief Executive Officer of Chiquita Brands International, Inc. (Chiquita), a global distributor of consumer products, having served as Chiquita's President and Chief Executive Officer from January 2004 to October 2012 and its Chairman from May 2004 to October 2012. Prior to joining Chiquita, Mr. Aguirre worked for more than 23 years in brand management, general management and turnarounds at The Procter & Gamble Company (P&G), a manufacturer and distributor of consumer products. Mr. Aguirre began his P&G career in 1980, serving in various capacities including President and General Manager of P&G Brazil, President of P&G Mexico, Vice President of P&G's global snacks and U.S. food products, and President of global feminine care. Mr. Aguirre was a member of the board of directors of Aetna from 2011 until the closing of the closing of Aetna's merger transaction with CVS Health in 2018 (the Aetna Transaction), when he became a director of CVS Health. Mr. Aguirre also serves as a director of Barry Callebaut AG, a manufacturer of high-quality chocolate and cocoa products, and is chair of its nomination and compensation committee, and as a director of Synchrony Financial, a consumer financial services company, and is chair of Synchrony's nominating and corporate governance committee. Other Public Boards: Barry Callebaut AG; Synchrony Financial. Education: B.S., Southern Illinois University, Edwardsville.
Mr. Brown has been a partner of Nelson Mullins Riley & Scarborough LLP (Nelson Mullins), a national law firm, since the August 2018 merger of Nelson Mullins and the Florida-based Broad and Cassel, of which Mr. Brown was Chairman from March 2000 through the time of the merger. He was also a member of the executive committee of Nelson Mullins until he rotated off the committee in December 2021. He served as the lead director of Rayonier Advanced Materials Inc., a leading specialty cellulose production company, until his retirement from that board in May 2020. Mr. Brown previously served on the board of Caremark Rx, Inc. from March 2001 until the closing of the merger transaction involving CVS Health and Caremark, when he became a director of CVS Health. Education: B.S.B.A., University of Florida; J.D., University of Florida College of Law.
Dr. Balser has served as the chief executive of Vanderbilt University Medical Center (VUMC) since 2009 and has been President and Chief Executive Officer since 2016, when VUMC became an independent health care company. He has also served as the Dean of the Vanderbilt University School of Medicine since 2008. Dr. Balser is a member of the National Academy of Medicine and serves on its governing council. He previously served on the board of Varian Medical Systems, Inc., an oncology treatment device and software maker that was publicly traded, from October 2018 until Varian was acquired by Siemens Healthineers AG in April 2021. Education: B.S., Tulane University; M.D. and Ph.D., Vanderbilt University.
Mr. Kirby has been the Chief Executive Officer and a member of the Board of Directors of United Airlines Holdings, Inc. (United Airlines), an international air carrier, since May 2020. Mr. Kirby also serves on the Executive Committee and the Finance Committee of the United Airlines Board of Directors. From August 2016 until May 2020, Mr. Kirby was President of United Airlines and was responsible for its operations, marketing, sales, alliances, network planning and revenue management. Prior to joining United Airlines, he was President of American Airlines from December 2013 until August 2016 and was President of US Airways from September 2006 until December 2013, when US Airways merged with American Airlines. He started his career at the Pentagon and in the technology sector. Mr. Kirby is a member of the Board of Directors of SONIFI Solutions, a privately held manufacturer of integrated technology and service platforms. He also currently serves as the Chairman of the Star Alliance Chief Executive Board, a global alliance consisting of 26 member airlines, and is a member of the Board of Governors of the International Air Transport Association, a trade association comprised of 240 of the world's airlines. Mr. Kirby is also a member of the Board of Directors of the U.S. Air Force Academy Foundation. Other Public Board: United Airlines Holdings, Inc. Education: B.S., U.S. Air Force Academy; M.S., George Washington University
Mr. Shulman has served as Chief Executive Officer of OneMain Holdings, Inc., a financial services company that is a leader in offering nonprime customers responsible access to credit, since 2018, and has been Chairman of the Board of OneMain since 2021. Prior to joining OneMain, Mr. Shulman was Senior Executive Vice President, Global Head of Client Service Delivery and was a member of the Executive Committee at BNY Mellon, a global financial services firm. Prior to BNY Mellon, he was a Senior Advisor at McKinsey & Company, and from 2008 to 2012, he served as the Commissioner of the Internal Revenue Service, where he directed a transformation of the agency's technology, drove customer service metrics to historic levels and led important breakthroughs in addressing international tax evasion. Previously, Mr. Shulman was Vice Chairman and, before that, President of Markets, Services and Information at FINRA and its predecessor company, NASD, when it owned the Nasdaq Stock Market and the American Stock Exchange. Other Public Board: OneMain Holdings, Inc. Education: B.A., Williams College, M.P.A., Harvard JFK School of Government, J.D., Georgetown University.
Ms. DeCoudreaux is President Emerita of the former Mills College, a liberal arts college for women with graduate programs for women and men, which is now known as Mills College at Northeastern University, having served a five-year term as President from July 2011 through June 2016. Previously, Ms. DeCoudreaux served in a number of leadership roles at Eli Lilly and Company, a global pharmaceutical manufacturer (Eli Lilly), including as Vice President and Deputy General Counsel, Specialty Legal Team, from 2010-2011, Vice President and General Counsel, Lilly USA, from 2005-2009, and Secretary and Deputy General Counsel of Eli Lilly from 1999-2005. During her 30-year career with Eli Lilly, Ms. DeCoudreaux also previously served as Executive Director of Lilly Research Laboratories, Director of Federal Government Relations, Director of State Government Relations and Director of Community Relations. In addition, Ms. DeCoudreaux has served on a number of charitable, educational, for profit and nonprofit boards, including as both a trustee and board chair at Wellesley College. She currently serves as Lead Independent Trustee and Chair of the Board of Trustees of Parnassus Funds/Parnassus Income Funds, a family of investment funds that integrates environmental, social and governance factors and fundamental investment principles. Other Public Board: Parnassus Funds/Parnassus Income Funds. Education: B.A., Wellesley College; J.D., Maurer School of Law at Indiana University.
Ms. Norwalk has served as Strategic Counsel to health care companies at Epstein, Becker & Green, P.C., a national law firm, since 2007. She also advises companies through EBG Advisors, a national strategy and management consultancy, and National Health Advisors, an advocacy firm. She serves as an advisor to private equity investors, including three private equity firms, particularly on health care matters. Ms. Norwalk currently sits on the boards of directors of Arvinas, Inc., a biotechnology company, ModivCare Inc., a technology-enabled healthcare services company, Neurocrine Biosciences, Inc., a biopharmaceutical company, Globus Medical, Inc., a medical device company, and several privately held health care entities. She is also a member of APCO Worldwide's International Advisory Council. Ms. Norwalk formerly sat on the boards of NuVasive, Magellan Health, Centene and Endologix, among others, and is the former Acting Administrator for the U.S. Centers for Medicare & Medicaid Services (CMS) under the George W. Bush administration. Other Public Boards: Arvinas, Inc., ModivCare Inc., Neurocrine Biosciences, Inc. and Globus Medical, Inc. (plans to step down from one public company board this proxy season). Education: B.A., Wellesley College, J.D., George Mason University
On March 18, 2026, the Board of Directors of the Company elected John E. Gallina to serve on the Board, effective March 19, 2026. Mr. Gallina is the former Executive Vice President and Chief Financial Officer (CFO) of Elevance Health, Inc. (Elevance; NYSE: ELV) a leading health benefits provider. Mr. Gallina served in the CFO role for Elevance from June 2016 through November 1, 2023, then served as EVP and Advisor to the CEO from November 1, 2023 until May 2024, when he retired. During the course of his nearly 30-year career with Elevance, Mr. Gallina held a number of finance and audit-related roles, including Chief Accounting Officer and Chief Risk Officer. Prior to joining Elevance, Mr. Gallina was a senior audit manager and a certified public accountant at Coopers & Lybrand. Mr. Gallina has a bachelor's degree in business administration from The Ohio State University. Mr. Gallina is currently a member of the Board of Directors of Arrive AI Inc. (Nasdaq: ARAI), a developmental technology company with a focus on autonomous deliveries, and is chair of Arrive AI's audit committee. Mr. Gallina is also a member of the boards of privately held non-profit entities The Allied Solutions Center for the Performing Arts (Carmel, IN) and the Western Golf Association/Evans Scholars Foundation.
James D. Clark, age 60, Senior Vice President - Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.
The Board of Directors of CVS Health appointed Amy L. Compton-Phillips, M.D. to serve as Executive Vice President and Chief Medical Officer of CVS Health, effective May 19th, 2025. Dr. Compton-Phillips was most recently chief physician executive of Press Ganey, a health care performance improvement company, and has an extensive background in directing patient care programs and leading health care organizations to broad-based improvements. Prior to Press Ganey, Dr. Compton-Phillips was the president and chief clinical officer at Providence Health & Services, a health care system, responsible for clinical operations and care including improving health, care, and value outcomes delivered by the system's hospitals, clinics, and caregivers. From 1985 to 2007, she held positions of increasing responsibility at Kaiser Permanente. Dr. Compton-Phillips earned her bachelor's degree from Johns Hopkins University and her medical degree from the University of Maryland School of Medicine. She is a board-certified internist.
数据来自SEC申报文件(经富途提供)。薪酬为已记录最近财年的报告总薪酬,不仅是基本工资。
暂无评论——快来第一个聊聊 CVS。
登录后参与讨论。